Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BREVITY: A Phase II Study of Brentuximab Vedotin Using a Response Adapted Design in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity

NCT02567851 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT02567851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02567851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BREVITY: A Phase II Study of Brentuximab Vedotin Using a Response Adapted Design in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity
Lead sponsor
University of Birmingham
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
October 2, 2017
Enrollment
38 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin disease